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Background: Various chemotherapies have been used as best practice to treat recurrent biliary malignancies.
Conversely, relatively few surgeries have been described for recurrent extrahepatic biliary carcinoma (RExBC), so
whether surgery for RExBC is feasible has remained unclear. This retrospective study was conducted to evaluate the
feasibility of surgery for RExBC.
Methods: From February 2000 to January 2014, a total of 27 patients, comprising 18 patients with extrahepatic
cholangiocarcinoma and 9 patients with gallbladder carcinoma, met our criteria for radical resection of RExBC
(resection group). Sites of recurrence consisted of liver metastases (ten patients), local/percutaneous transhepatic
cholangio drainage (PTCD) fistula recurrence (eight patients), bile duct recurrence (six patients), and lymph node
recurrence (one patient). To evaluate the survival impact of resection, we compared 123 RExBC patients (resection
group) with patients who received palliative care (palliative group).
Results: Morbidity and mortality rates in the resection group were 6.6% and 0%, respectively. Overall cumulative
5-year survival rates were 23.5% in the resection group and 0% in the palliative group. Median survival time was
21.6 months in the resection group and 9.5 months in the palliative group, showing a significant difference
(p < 0.01). No significant differences in cumulative survival were seen between extrahepatic cholangiocarcinoma
and gallbladder carcinoma in the resection group. In addition, no significant differences were seen between liver
metastases, bile duct recurrence, and local/percutaneous transhepatic biliary drainage (PTBD) fistula recurrence in
the resection group.
Conclusions: Surgery appears feasible for RExBC and offers longer survival for selected patients.
Keywords: Recurrent biliary malignancy, Extrahepatic cholangiocarcinoma, Gallbladder carcinoma, Surgery,
Chemotherapy, SurvivalBackground
Long-term survival rates for extrahepatic biliary
carcinoma (extrahepatic cholangiocarcinoma and gall-
bladder carcinoma) are thought to be improving. Five-
year cumulative survival rates have been reported as
22 to 40% for extrahepatic cholangiocarcinoma and
8 to 65% for advanced gallbladder carcinoma [1-7].
For now, no evidence supports the use of adjuvant
chemotherapy [8].* Correspondence: drnoji@med.hokudai.ac.jp
Department of Gastroenterological Surgery II, Hokkaido University Graduate
School of Medicine, Kita 15 Nishi 7, Kita-ku, Sapporo, Hokkaido 0608638,
Japan
© 2015 Noji et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.For recurrent biliary malignancies, various chemother-
apies have been used as best practice [9]. Conversely,
few surgeries for recurrent extrahepatic biliary carcin-
oma (RExBC) have been reported, because secondary (or
more) resection for RExBC is known as an extremely
demanding procedure. Most patients with extrahepatic
biliary carcinoma undergo complex anatomical resection
and reconstruction with radical lymphadenectomy around
the hepatoduodenal ligament (skeletonization) in the pri-
mary surgery. Few reports have described surgical inter-
ventions for RExBC, and those have mostly been case
reports [10-14]. Whether surgery for RExBC is feasible
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Age (years)a 71 (45 to 83)b 71 (48 to 84)b 0.77





Gallbladder carcinoma 9 27
Recurrent site (cases)
Liver 10 34 -
Bile duct 6 5
Lymph node 1 14












aAge at recurrence. bValues represent median (range) for each parameter.
PTBD, percutaneous transhepatic biliary drainage.
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for RExBC since 2000. This retrospective study was con-
ducted to evaluate the feasibility of surgery for RExBC
following radical operation.
Methods
Surgical indications for RExBC
Surgical indications for RExBC in our department at the
time of the study were as follows:
A). All surgical intervention should be intended as R0
curative resection. Resectability was determined
from several imaging modalities (computed
tomography, magnetic resonance imaging,
ultrasonography, endoscopic ultrasonography,
18 F-fluorodeoxy glucose positron emission
tomography). If multiple peritoneal disseminations
or multiple metastases that were unable to be
resected with curative intent were found, palliative
procedures (gastrointestinal bypass or exploratory
laparotomy only) were selected.
B). All candidates for surgical intervention were observed
for at least 3 months with or without chemotherapy
before resection. In addition, all candidates for
surgical intervention should have isolated metastatic
lesions. If a new metastatic lesion was found during
this period, surgical intervention was not selected.
C). All candidates should have performance status 0 or 1
according to Eastern Cooperative Oncology Group
criteria [15]. We used our criteria for hepatectomy in
biliary malignancies, as described previously [16].
Anatomical variation and tumour location were also
considered in determining resectability.
Patients
From February 2000 to January 2014, a total of 150 pa-
tients with RExBC were identified for whom follow-up
of the complete clinical course in our department was
available. Among these patients, a total of 27 patients
(21 men, 6 women; median age 71 years; age range 45
to 83 years) met our surgical criteria for RExBC. The
underlying pathology was extrahepatic cholangiocarci-
noma in 18 patients and gallbladder carcinoma in 9 (re-
section group).
To evaluate the survival impact of resection for RExBC,
we reviewed the remaining 123 unresectable patients
(92 men, 31 women; median age 71 years; range 48 to
84 years) with RExBC (palliative group). This palliative
group included eight patients who underwent explora-
tory laparotomy.
Type of recurrence
Recurrent sites consisted of liver metastases, local/per-
cutaneous transhepatic biliary drainage (PTBD) fistularecurrence, bile duct recurrence, lymph node recurrence,
and lung metastasis. Participants comprised ten patients
with liver metastases, eight patients with PTBD fistula re-
currence, six patients with bile duct recurrence, one patient
with lymph node recurrence, and two patients with lung
metastasis in the resection group, respectively (Table 1).
Concerning patients in the palliative group who under-
went exploratory laparotomy, six patients with local/
PTBD recurrence showed peritoneal dissemination, and
the remaining two patients with lymph node recurrence
showed multiple lymph node metastases that were un-
able to be resected completely.
Surgical procedure
All resections were planned to have sufficient surgical mar-
gins. For liver metastases, several types of hepatectomy
were performed. We planned various types of surgeries for
local/PTBD fistula recurrence with sufficient margins. For
bile duct recurrence, various major hepatectomies or pan-
creaticoduodenectomies were performed. For lymph nodal
metastases, metastatic lymph node resection with concomi-
tant resection of surrounding organ was performed. For
lung metastases, partial lung resections were performed.
Morbidity and mortality
The Clavien-Dindo classification was used for defining mor-
bidity and mortality [17]. Postoperative complications ≥ IIIa
in the Clavien-Dindo classification were defined as morbidity.
Table 2 Surgical procedure and results in the resection









Chest wall resection 1
Chest wall resection + non-anatomical hepatectomy 2
Non-anatomical hepatectomy + IVC/jejunum/colon/
diaphragm resection
1
Para-aortic lymphadenectomy + adrenalectomy 1
Morbidity (Clavien-Dindo≥ IIIa) (cases) 2
Mortality (cases) 0
IVC, inferior venous cava.
Figure 1 Survival in the resection and palliative groups.
Cumulative 3- and 5-year survival rates in the patient resection group
were 31% and 23%, respectively. Cumulative 3-year survival rate for
patients in the palliative group was 0%. Significant differences were
seen in survival between these two groups (p < 0.01).
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To evaluate the survival impact of RExBC, we calculated
the length from the day on which recurrence was identi-
fied in this study.
Statistics
Statistical calculations were performed using Stat Flex soft-
ware (Artech, Osaka, Japan) and the ‘Exact Test’ produced
by Prof. S. Aoki (http://aoki2.si.gunma-u.ac.jp/exact/exact.
html). The chi-square test, Fisher’s exact, and Mann–
Whitney U tests were used as appropriate. Cumulative
survival after surgery was calculated using the Kaplan-
Meier method. The log-rank test was used to compare
cumulative survival. Values of p < 0.05 were considered
significant.
Consent
This study was approved by the local institutional re-
view board of Hokkaido University Hospital. And writ-
ten informed consent was obtained from the patient for
the publication of this report and any accompanying
images.
Results
Two patients in the resection group underwent repeated
resections for metastases. One patient with liver metas-
tases underwent three resections, and the other patient
with lung metastases underwent two resections. We per-
formed 30 surgeries for the resection group, and 8 ex-
ploratory laparotomies in the palliative group. The
resectability rate for the entire series was thus 79%.
Disease-free intervals (DFIs) in the resection and pallia-
tive groups were 25.1 months (range 10.3 to 112.6 months)
and 13.0 months (range 1.8 to 124.2 months), respectively.
Significant differences in DFI were seen between the two
groups (p < 0.01, Table 1).
We applied 30 various surgical procedures for the 27
cases in the resection group. Procedures and surgical re-
sults for the resection group are shown in Table 2. Mor-
bidity and mortality rates were 6.6% and 0%, respectively.
The overall cumulative 5-year survival rate was 23.6% in
the resection group and 0% in the palliative group. Median
survival time was 21.6 months in the resection group and
9.5 months in the palliative group, showing a significant
difference between groups (p < 0.01) (Figure 1).
Three patients in the resection group achieved 5-year
survival (one patient with liver metastases, one with
lymph node metastasis, and one with local/PTBD fistula
recurrence).
No significant differences in cumulative survival were
seen between extrahepatic cholangiocarcinoma and
gallbladder carcinoma in the resection group. No sig-
nificant differences between liver metastases, bile duct
recurrence, or local/PTBD fistula recurrence were seenin the resection group (Figure 2). Likewise, no signifi-
cant differences were seen in survival between DFI >24
and ≤24 months (p = 0.25).
No significant differences in survival were evident be-
tween extrahepatic cholangiocarcinoma and gallbladder
carcinoma in the resection group patients (Figure 3).
Discussion
In general, almost all patients with recurrent biliary malig-
nancy are treated using various chemotherapies. Some trials
Figure 2 Survival differences according to primary disease.
Cumulative 3- and 5-year survival rates for extrahepatic
cholangiocarcinoma were 25% and 12%, respectively. Cumulative
3- and 5-year survival rates for gallbladder carcinoma were 43%
each. No significant differences were seen in survival between
these groups (p = 0.37).
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could provide clinical benefit to patients with recurrent
biliary malignancies [9,18-21]. However, these chemo-
therapies had few patients with long-term survival, and
median survival times have been reported as less than
13 months [9,18-21].
One of the most important questions for RExBC is
whether surgical intervention is feasible. Our results
suggest that surgical intervention for RExBC might beFigure 3 Survival differences between local/PTBD fistula
recurrence, liver metastasis, and bile duct recurrence.
Cumulative 3-year survival rates in local/PTBD fistula recurrence,
liver metastasis, and bile duct recurrence were 50%, 33%, and 0%,
respectively. Cumulative 3-year survival rate in local/PTBD fistula
recurrence, liver metastasis, and bile duct recurrence were 50%, 17%,
and 0%, respectively. No significant differences were seen in survival
among these three groups.worth considering. Cumulative 5-year survival rate in
the resection group was 23.6%. We had low morbidity
and no mortality in this series, and three patients sur-
vived for more than 5 years.
Concerning surgical indications for RExBC, only 1 re-
port has referred to surgical results for RExBC; Song
et al. reported surgical results for 27 patients with recur-
rent cholangiocarcinoma [22]. They showed that surgical
resection for recurrent cholangiocarcinoma offers signifi-
cant benefits for survival. However, because they merged
recurrent intrahepatic cholangiocarcinoma (ICC) and re-
current extrahepatic cholangiocarcinoma and did not
show operative results (operation time, operative bleeding,
morbidity, or mortality) for their series, surgical indica-
tions for RExBC have remained unclear.
In terms of surgical intervention for recurrent ICC,
few reports are available, and those reports have shown
that surgical intervention for recurrent ICC would be
feasible. Saiura et al. described five cases of repeat hepa-
tectomy [23]. They had two patients with long-term sur-
vival. Okusaka et al. showed results for nine patients
with various types of resection [19]. They performed cura-
tive resection for six of the nine patients and achieved
relatively long survival for three. Fu et al. reported results
for 19 patients with recurrent ICC treated using radiofre-
quency ablation (RFA) [24]. They showed a median overall
survival of 30 months, and 1- and 3-year survival rates of
87.5% and 37.5%, respectively.
Quite substantial differences might be thought to exist
between extrahepatic cholangiocarcinoma and gallblad-
der carcinoma. However, recent studies for recurrent bil-
iary carcinoma, such as the ABC-01 study and BT22
study, have included various types of RExBC [19,21].
Furthermore, our data showed no significant differences
between extrahepatic cholangiocarcinoma and gallblad-
der carcinoma in either the palliative or the resection
group. We therefore considered that inclusion of both
extrahepatic cholangiocarcinoma and gallbladder carcin-
oma in our study was proper.
For gastrointestinal malignancies, the efficacy of repeat
hepatectomy for colorectal liver metastases is widely ac-
cepted; however, the benefits of such treatment for intra-
hepatic recurrence of gastric cancer liver metastasis
remain unclear [25-27]. Most patients have been treated
using various chemotherapies [28]. This situation is
thought to be similar to that for RExBC. However, several
reports have suggested that hepatectomy for metastatic le-
sions from gastric cancer would lead to long-term survival
[25-27,29]. Takemura et al. showed results for 64 gastric
cancer patients with liver metastasis. They showed that
median overall survival was 34 months, with 3- and 5-year
survival rates of 50 and 37%, respectively [26]. Baek et al.
showed similar results [29]. Hwang et al. showed
favourable median survival (27 months) for patients with
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These results of recurrent ICC, gastric cancer, and our re-
sults for RExBC might suggest that surgical intervention
for selected patients with RExBC is feasible.
The next question is that if surgical intervention for
RExBC is indeed feasible, for whom and when should
surgery be performed?
We used two major criteria for surgical intervention
for RExBC. Nobody would doubt our criterion that all
surgical procedures should be performed with the
intention of R0 curative resection. In other words, every
patient for whom R0 resection is considered possible
would represent a surgical candidate.
Concerning the site of recurrence, we achieved suc-
cessful resection for all candidates with bile duct recur-
rence and liver metastasis. Three of ten patients with
liver metastasis were able to survive over 3 years after
resection at the site of recurrence.
For bile duct recurrences, we have some doubts about
surgical indications. We needed to perform demanding
extended resection in the form of major hepatectomy or
pancreaticoduodenectomy. However, the survival rate
with bile duct recurrence tended to be lower than that
with other types of recurrence, although no significant
differences were identified (Figure 3).
We achieved lower resectability rates for patients with
local/PTBD recurrence or lymph node recurrence than
for patients with other recurrences. That means some
patients were not adequately diagnosed in the preopera-
tive survey. Our previous reports have shown that diag-
nosing lymph node metastasis preoperatively is difficult
[30,31]. Diagnosing peritoneal disseminations preopera-
tively must likewise be difficult [32].
However, our data only included a small number of pa-
tients with peritoneal metastases or para-aortic lymph
node metastasis for resection with curative intent. We
achieved long survival for patients with para-aortic lymph
node metastasis or local/PTBD fistula recurrence (‘local-
ized’ peritoneal recurrence), and one patient achieved
more than a 5-year survival. This suggests that surgical
intervention is also feasible for selected patients with
local/PTBD or lymph node recurrence.
When should surgery be performed? We observed all
surgical candidates for at least 3 months with or without
chemotherapy before surgery. This criterion was intro-
duced based on our personal experience without object-
ive evidence as such. However, we believe this criterion
could allow exclusion of patients with a ‘rapidly growing
tumor’ or patients with a ‘widely disseminating tumor.’
With regard to the timing of surgery, no significant cri-
teria have been described in recurrent ICC series [19,23,24].
On the other hand, in patients with liver metastases from
gastric cancer, Takemura identified disease-free interval,
tumour size, and primary tumour stage as prognosticfactors for survival [26,27]. Our data showed no significant
effect of operative interval on survival.
Our criteria for RExBC led us to a 79% resectability
rate, which was considered satisfactory.
This study had several limitations. First, it was a small,
retrospective study and was not an intention-to-treat ana-
lysis. Whether surgical intervention is feasible thus remains
in question. Second, whether neoadjuvant or adjuvant ther-
apy is effective for resectable RExBC also remains unclear.
Third, this study excluded carcinoma of the papilla of
Vater. The feasibility of surgery for recurrent carcinoma of
the papilla of Vater thus remains unclear.
These limitations would be best addressed in a future
multi-centre study.
Conclusions
In conclusion, despite these limitations, surgical inter-
vention appears to offer improved survival in select pa-
tients with RExBC. Appropriate surgical indications and
adjuvant therapy for RExBC should be investigated in a
larger-scale study.
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